Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | COXFA4 | O00483 | 1/20 | 0.31 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.30 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
| ▸ | RXRA | P19793 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28783308 | 0.85 | MEN1 (0.31) | MEN1KMT2ACOXFA4GPR119PARP1 | |
| SCHEMBL15579052 | 0.83 | MAPT (0.33) | MEN1KMT2ACOXFA4 | |
| SCHEMBL925393 | 0.80 | AVPR1A (0.37) | MEN1KMT2AGPR119ABCB1 | |
| SCHEMBL14357334 | 0.77 | ATM (0.50) | MEN1KMT2ARXRA | |
| SCHEMBL829418 | 0.76 | GNG2 (0.40) | MEN1KMT2ARXRA | |
| SCHEMBL30563103 | 0.76 | GNG2 (0.40) | MEN1KMT2ARXRA | |
| SCHEMBL27636279 | 0.76 | ATM (0.36) | MEN1KMT2ACOXFA4PTGS1PTGS2 | |
| SCHEMBL30983074 | 0.76 | TSHR (0.41) | RXRA | |
| SCHEMBL925394 | 0.75 | MT-CO2 (0.32) | GPR119 | |
| SCHEMBL960318 | 0.74 | MAPT (0.46) | KMT2ARXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114736186-A | Method for synthesizing vilanterol intermediate from tert-butyl carbamate | 安徽德信佳生物医药有限公司 | 2022-07-12 | — | — | CN | disclosed |
| US-20150239862-A1 | PROCESS FOR THE PREPARATION OF VILANTEROL AND INTERMEDIATES THEREOF | PERRIGO API LTD. (IL) | 2015-08-27 | — | — | US | disclosed |
| US-20150239862-A1 | PROCESS FOR THE PREPARATION OF VILANTEROL AND INTERMEDIATES THEREOF | PERRIGO API LTD. (IL) | 2015-08-27 | — | — | US | disclosed |
| US-RE44874-E1 | Phenethanolamine derivatives for treatment of respiratory diseases | GLAXO GROUP LIMITED (GB) | 2014-04-29 | — | — | US | disclosed |
| WO-2014041565-A2 | AN IMPROVED PROCESS FOR THE PREPARATION OF VILANTEROL AND INTERMEDIATES THEREOF | LAURUS LABS PRIVATE LIMITED (IN) | 2014-03-20 | — | — | WO | disclosed |
| EP-2042168-B1 | Inhalation formulation comprising phenethanolamine derivatives for the treatment of respiratory diseases | GLAXO GROUP LTD (GB) | 2013-10-23 | — | — | EP | disclosed |
| US-8198483-B2 | Phenethanolamine derivatives for treatment of respiratory diseases | GLAXO GROUP LIMITED (GB) | 2012-06-12 | — | — | US | disclosed |
| US-20110269970-A1 | Phenethanolamine Derivatives for Treatment of Respiratory Diseases | GLAXO GROUP LIMITED (GB) | 2011-11-03 | — | — | US | disclosed |
| US-7982067-B2 | Phenethanolamine derivatives for treatment of respiratory diseases | GLAXO GROUP LIMITED (GB) | 2011-07-19 | — | — | US | disclosed |
| US-20110009631-A1 | Phenethanolamine Derivatives for Treatment of Respiratory Diseases | GLAXO GROUP LIMITED (GB) | 2011-01-13 | — | — | US | disclosed |
| EP-1395604-A1 | NOVEL ANTI INFLAMMATORY 17.ALPHA.-HETEROCYCLIC-ESTERS OF 17.BETA.-CARBOTHIOATE ANDROSTANE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2004-03-10 | — | — | EP | disclosed |
| EP-1366025-A1 | AGONISTS OF BETA-ADRENOCEPTORS | GLAXO GROUP LIMITED (GB) | 2003-12-03 | — | — | EP | disclosed |
| EP-1360174-A1 | PHENETHANOLAMINE DERIVATIVES FOR TREATMENT OF RESPIRATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2003-11-12 | — | — | EP | disclosed |
| WO-2003091204-A1 | PHENETHANOLAMINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2003-11-06 | — | — | WO | disclosed |
| WO-2003072539-A1 | PHENETHANOLAMINE DERIVATIVES FOR TREATMENT OF RESPIRATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2003-09-04 | — | — | WO | disclosed |
| WO-2003035668-A2 | NOVEL ANTI-INFLAMMATORY ANDROSTANE DERIVATIVES -17-CARBOXY-LACTONE SUBSTITUTED STEROIDS WITH AN ARYL-CARBOXYLIC ESTER IN POSITION 17.ALPHA | GLAXO GROUP LIMITED (GB) | 2003-05-01 | — | — | WO | disclosed |
| WO-2003024439-A1 | PHENETHANOLAMINE DERIVATIVES FOR TREATMENT OF RESPIRATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2003-03-27 | — | — | WO | disclosed |
| WO-2002100879-A1 | NOVEL ANTI-INFLAMMATORY 17.ALPHA.-HETEROCYCLIC-ESTERS OF 17.BETA.CARBOTHIOATE ANDROSTANE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2002-12-19 | — | — | WO | disclosed |
| WO-2002070490-A1 | AGONISTS OF BETA-ADRENOCEPTORS | GLAXO GROUP LIMITED (GB) | 2002-09-12 | — | — | WO | disclosed |
| WO-2002066422-A1 | PHENETHANOLAMINE DERIVATIVES FOR TREATMENT OF RESPIRATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2002-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150239862-A1 | PROCESS FOR THE PREPARATION OF VILANTEROL AND INTERMEDIATES THEREOF | VAT1, VKORC1L1, VKORC1 | MEN1 3270/4885KMT2A 3964/4885COXFA4 1320/4885 |
| US-20110269970-A1 | Phenethanolamine Derivatives for Treatment of Respiratory Diseases | PNMT, HRH2, CHKB | MEN1 3658/4885KMT2A 257/4885COXFA4 1140/4885 |
| US-20110009631-A1 | Phenethanolamine Derivatives for Treatment of Respiratory Diseases | PHOSPHO1, PNMT, PEBP1 | MEN1 1526/4885KMT2A 369/4885COXFA4 247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.